Neoadjuvant therapy in breast cancer;Cancer du sein: Place du traitement néoadjuvant

Revue Medicale de Bruxelles

Volumn 32, Issue 4, 2011, Pages 243-246

  Ena, G ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Breast cancer; Neoadjuvant therapy

Indexed keywords

TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; HUMAN; POSTOPERATIVE CARE; REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 80053911068     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Seo JH, Kim YH, Kim JS : Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer. Cancer Chemother Pharmacol 2009; 63 : 261-6
2. Gianni L, Eiermann W, Semiglazov V et al. : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375 : 377-84
3. Perez CA, Fields JN, Fracasso PM et al. : Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer 1994; 74 : 466-76. (Pubitemid 24187665)
4. Bear HD, Anderson S, Smith RE et al. : Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24 : 2019-27
5. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B : Preoperative chemotherapy in patients with operable breast cancer : nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30 : 96-102
6. Kell MR, Morrow M : Surgical aspects of inflammatory breast cancer. Breast Dis 2005; 22 : 67-73 (Pubitemid 44308943)
7. Kuerer HM, Newman LA, Smith TL et al. : Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17 : 460-9 (Pubitemid 29075229)
8. Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N : Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989; 49 : 2002-4 (Pubitemid 19106504)
9. Tan VK, Goh BK, Fook-Chong S, Khin LW, Wong WK, Yong WS : The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer : a systematic review and meta-analysis. J Surg Oncol 2011; 104 : 97-103
10. Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK : The assessment of breast cancer response to neoadjuvant chemotherapy : comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. Acta Radiol 2011; 52 : 21-8
11. Preece PE, Wood RA, Mackie CR, Cuschieri A : Tamoxifen as initial sole treatment of localised breast cancer in elderly women : a pilot study. Br Med J (Clin Res Ed) 1982; 284 : 869-70 (Pubitemid 12185510)
12. Eiermann W, Paepke S, Appfelstaedt J et al. : Preoperative treatment of postmenopausal breast cancer patients with letrozole : A randomized double-blind multicenter study. Ann Oncol 2001; 12 : 1527-32 (Pubitemid 34065880)
13. Smith IE, Dowsett M, Ebbs SR et al. : Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination : the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23 : 5108-16 (Pubitemid 46224019)
14. Cataliotti L, Buzdar AU, Noguchi S et al. : Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106 : 2095-103 (Pubitemid 43673229)
15. Ellis MJ, Tao Y, Luo J et al. : Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100 : 1380-8
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 : 1659-72 (Pubitemid 41464705)
17. Buzdar AU, Ibrahim NK, Francis D et al. : Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy : results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23 : 3676-85
18. Baselga J, Bradbury I, Eidtmann H et al. : Final Results of the NeoALTTO Trial (BIG01-06 / EGF106903) : A Phase III, randomized, open-label, neo-adjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium, 2010 : S3-3
19. Gianni L, Pienkowski T, Im Y-H et al. : Neoadjuvant pertuzumab and trastuzumab : Antitumor and safety analysis of a randomized phase II study (NeoSphere). San Antonio Breast Cancer Symposium, 2010; S3-2